학술논문
Reevaluating the FDA's warning against the use of probiotics in preterm neonates: a societal statement by ESPGHAN and EFCNI
Document Type
Author
van den Akker, Chris H. P.; Embleton, Nicholas D.; Lapillonne, Alexandre; Mihatsch, Walter A.; Salvatore, Silva; Canani, Roberto B.; Dinleyici, Ener C.; Domellöf, Magnus, 1963; Guarino, Alfredo; Gutiérrez-Castrellón, Pedro; Hojsak, Iva; Indrio, Flavia; Mosca, Alexis; Orel, Rok; van Goudoever, Johannes (Hans) B.; Weizman, Zvi; Mader, Silke; Zimmermann, Luc J. I.; Shamir, Raanan; Vandenplas, Yvan; Szajewska, Hania
Source
Journal of Pediatric Gastroenterology and Nutrition - JPGN. 78(6):1403-1408
Subject
Language
English
ISSN
0277-2116
1536-4801
1536-4801
Abstract
The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.